Studying immune therapy response in lung cancer patients
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at how the immune system reacts to standard treatments for non-small cell lung cancer. It may help doctors understand why some patients respond better to treatment, which could guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were treated for stage III non-small cell lung cancer with surgery, followed by chemotherapy and radiation (chemoradiotherapy) and then maintenance therapy between September 2018 and December 2021.
- You did not receive chemotherapy, radiation, or immune therapy before your surgery.
- You have not had any other cancer before this one.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at lung cancer samples you provide to see how tumor cells respond to treatment. It may help researchers find better ways to choose treatments for lung cancer by testing response in a lab model.
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
This study collects blood and sputum (phlegm) samples from people with lung cancer before and during immunotherapy. The goal is to see if certain immune markers in these samples can predict how well the treatment works.
This study looks at how your immune system works in non-small cell lung cancer and whether it predicts how well you'll respond to a type of immunotherapy called anti-PD-1/PD-L1 drugs. Researchers will study your tumor tissue to understand why some patients benefit more than others.
This trial studies how well immune checkpoint medicines (with or without chemotherapy) work for lung cancer, and looks for biomarkers—tests that may help predict who benefits. It may help you access a structured treatment plan and additional response testing.
This study looks at how your body reacts to checkpoint inhibitors (immunotherapy drugs like Keytruda or Opdivo) for NSCLC. It involves blood tests to check for antibodies your immune system might make against the drug.
Hear when a new Lung Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.